Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Biogen said it published a prespecified Phase 3 VALIANT adolescent subgroup analysis in CJASN, reporting reductions in proteinuria and stabilized kidney function with EMPAVELI versus placebo in C3G or primary IC-MPGN.
Biogen said it has published a prespecified adolescent subgroup analysis from its Phase 3 VALIANT study of EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology.